公开(公告)号：US20210252028A1

公开(公告)日：2021-08-19

申请号：US17114850

申请日：2020-12-08

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K45/06 ,  A61P31/00 ,  A61P3/10 ,  A61P29/00 ,  A61K35/20

Abstract: A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.

公开(公告)号：US10828313B2

公开(公告)日：2020-11-10

申请号：US15104794

申请日：2015-12-08

Applicant: GLYCOM A/S

Inventor： Emma Salomonsson ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7012 ,  A61K31/7004 ,  A61K9/00

Abstract: The invention relates to a synthetic composition comprising one or more human milk monosaccharides and/or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and/or low-grade inflammation in patients with metabolic disorders.

公开(公告)号：US20200147114A1

公开(公告)日：2020-05-14

申请号：US16681626

申请日：2019-11-12

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs

IPC: A61K31/7048 ,  A23L33/125 ,  A61K9/20 ,  A61K31/702

Abstract: A composition consists of an effective amount of a synthetic neutral fucosylated human milk oligosaccharide (“HMO”), an effective amount of a synthetic neutral non-fucosylated HMO, and one or more excipients acceptable for enteral administration to a non-infant human. In some embodiments, the synthetic neutral fucosylated HMO is 2′-fucosyllactose and the synthetic neutral non-fucosylated HMO is selected from lacto-N-neotetraose (“LNnT”) and lacto-N-tetraose (“LNT”). In certain embodiments, the mass ratio of 2′-FL to the selected LNnT or LNT is about 1.5 to about 4.5. In one embodiment, the synthetic neutral non-fucosylated HMO is lacto-N-neotetraose (“LNnT”). In certain embodiments, the one or more excipients acceptable for enteral administration to a human are selected from diluents, antioxidants, lubricants, colorants, binders, disintegrants, and combinations thereof. In various embodiments, the one or more excipients are effective to form a galenic unit dosage form selected from a capsule, a tablet, and a sachet.

公开(公告)号：US10471084B2

公开(公告)日：2019-11-12

申请号：US15555936

申请日：2016-03-04

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs

IPC: A61K31/7048 ,  A61K31/702 ,  A61K9/20 ,  A23L33/125

Abstract: A composition and method for using it to prevent and/or relieve symptoms of acute respiratory tract infections, particularly bronchitis, in immune-compromised persons, particularly adults. The composition contains 2′-fucosyllactose and lacto-N-neotetraose and/or lacto-N-tetraose.

公开(公告)号：US20180185398A1

公开(公告)日：2018-07-05

申请号：US15906911

申请日：2018-02-27

Applicant: Glycom A/S

Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Emma Elison

IPC: A61K31/702 ,  A61P1/00 ,  A61K31/7016

CPC classification number: A61K31/702 ,  A61K31/7016 ,  A61P1/00

Abstract: This invention relates generally to compositions and methods for preventing or treating mast cell mediated visceral pain.

公开(公告)号：US20180177809A1

公开(公告)日：2018-06-28

申请号：US15903959

申请日：2018-02-23

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7016 ,  A61P1/12

CPC classification number: A61K31/702 ,  A61K31/7016 ,  A61K2300/00 ,  A61P1/12

Abstract: The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides.

公开(公告)号：US20180169122A1

公开(公告)日：2018-06-21

申请号：US15897099

申请日：2018-02-14

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Salomonsson ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A23C9/20 ,  A23L33/21 ,  A61K31/7012 ,  A61K31/7004

CPC classification number: A61K31/702 ,  A23C9/206 ,  A23L33/21 ,  A23V2002/00 ,  A61K31/7004 ,  A61K31/7012 ,  A61P1/04 ,  A61K2300/00

Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient a mixture comprising 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT).

公开(公告)号：US20180036327A1

公开(公告)日：2018-02-08

申请号：US15555936

申请日：2016-03-04

Applicant: Glycom A/S

Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs

IPC: A61K31/7048 ,  A61K31/702

CPC classification number: A61K31/7048 ,  A23L33/125 ,  A23V2002/00 ,  A61K9/205 ,  A61K9/2054 ,  A61K31/702 ,  A61K2300/00 ,  A23V2200/314 ,  A23V2200/3202 ,  A23V2250/28

Abstract: A composition and method for using it to prevent and/or relieve symptoms of acute respiratory tract infections, particularly bronchitis, in immune-compromised persons, particularly adults. The composition contains 2′-fucosyllactose and lacto-N-neotetraose and/or lacto-N-tetraose.

公开(公告)号：US20170258820A1

公开(公告)日：2017-09-14

申请号：US15523379

申请日：2015-10-29

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Salomonsson ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A23L33/125 ,  A61K31/7016 ,  A23L33/00 ,  A61K31/7012 ,  A61K31/7004

CPC classification number: A61K31/702 ,  A23L33/125 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/7004 ,  A61K31/7012 ,  A61K31/7016 ,  A61K35/20 ,  A61P1/04 ,  A61K2300/00

Abstract: The application relates to synthetic composition containing one or more human milk mono- or oligosaccharides which promote mucosal healing in inflammatory GI conditions of humans.

公开(公告)号：US20160310514A1

公开(公告)日：2016-10-27

申请号：US15104794

申请日：2015-12-08

Applicant: GLYCOM A/S

Inventor： Emma Salomonsson ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnaes

IPC: A61K31/702 ,  A61K9/00

Abstract: The invention relates to a synthetic composition comprising one or more human milk monosaccharides and/or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and/or low-grade inflammation in patients with metabolic disorders.

Abstract translation: 本发明涉及包含一种或多种人乳单糖和/或一种或多种用于降低代谢紊乱患者的肠通透性，内毒素血症和/或低度炎症的人乳寡糖的合成组合物。